Meeting
2023 ASCO Annual Meeting
A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors.
Authors
Jeffrey A. Bacha
Edison Oncology Holding Corp., Menlo Park, CA
Jeffrey A. Bacha , Dennis Brown , James I. Geller , Javier E. Oesterheld , Meghann McManus , Sarath Kanekal , Markos Leggas , Lorena Lopez , Neil Sankar , Noymi Yam , Lars M. Wagner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT04337177
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS10073)
DOI
10.1200/JCO.2023.41.16_suppl.TPS10073
Abstract #
TPS10073
Poster Bd #
375b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A pilot clinical study of VAL-413 (oral irinotecan HCl) in patients with recurrent pediatric solid tumors.
First Author: Dennis Brown
First Author: Stuart Cramer
Poster
2021 ASCO Annual Meeting
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
First Author: Jennifer Foster
Poster
2020 ASCO Virtual Scientific Program
A phase I/II study of eribulin mesilate (ERI) plus irinotecan (IRI) in children with refractory or recurrent solid tumors.
First Author: Michela Casanova